Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-13

Clinical Trial Update: TKI 258 in Von Hippel-Lindau Syndrome (VHL) [Phase 2]

View source ↗

Summary

Phase 2 trial of TKI 258 in Von Hippel-Lindau syndrome was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TKI 258

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Von Hippel-Lindau Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2017-02-13